# Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome

> **NCT02452983** · PHASE1 · TERMINATED · sponsor: **Gustavo Rivero** · enrollment: 14 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Sertraline
- **PROCEDURE:** Bone Marrow Aspirate/Biopsy

## Key facts

- **NCT ID:** NCT02452983
- **Lead sponsor:** Gustavo Rivero
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-05
- **Primary completion:** 2020-11
- **Final completion:** 2020-11
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** This protocol is closed to further enrollment due to lack of study progress.
- **Last updated:** 2022-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02452983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02452983, "Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02452983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*